Paolo Ghia, MD, PhD, describes the various cohorts of the SEQUOIA study, expands on outcomes from a biomarker subgroup analysis with zanubrutinib vs bendamustine plus rituximab, and more.
Paolo Ghia, MD, PhD, full professor, discusses a biomarker subgroup analysis of the phase 3 SEQUOIA trial investigating zanubrutinib vs bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletions.